Lamivudine in Late Pregnancy to Interrupt In Utero Transmission of Hepatitis B Virus: A Systematic Review and Meta-Analysis

@article{Shi2010LamivudineIL,
  title={Lamivudine in Late Pregnancy to Interrupt In Utero Transmission of Hepatitis B Virus: A Systematic Review and Meta-Analysis},
  author={Zhongjie Shi and Yue-bo Yang and Lin Ma and Xiaomao Li and Ann Schreiber},
  journal={Obstetrics \& Gynecology},
  year={2010},
  volume={116},
  pages={147-159}
}
OBJECTIVES: To evaluate efficacy of lamivudine in reducing in utero transmission of hepatitis B virus (HBV). DATA SOURCES: A database was constructed from Medline, EMBASE, Cochrane Library, National Science Digital Library, China Biological Medicine Database, and through contact with experts in the field from January 1990 to October 2009. METHODS OF STUDY SELECTION: We used the Jadad score and Cochrane Collaboration's tool for assessing risk of bias. TABULATION, INTEGRATION, AND RESULTS: We… Expand
Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis.
TLDR
Telbivudine is an effective and safe drug for preventing intrauterine transmission of HBV and it is shown that CK elevations and adverse effect frequencies were similar in both groups. Expand
A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus.
TLDR
Lamivudine treatment in HBV carrier-mothers from 28 wk of gestation may interrupt MTCT of HBV efficiently and is safe and more efficient than hepatitis B immunoglobulin in interrupting MTCT. Expand
The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis
TLDR
Preliminary evidence is provided that telbivudine application in late pregnancy is effective in the interruption of intrauterine HBV infection, with no significant adverse effects or complications. Expand
Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review.
TLDR
Breastfeeding after proper immunoprophylaxis did not contribute to MTCT transmission of HBV and no adverse events or complications during breastfeeding were observed. Expand
Lamivudine's efficacy and safety in preventing mother-to-child transmission of hepatitis B: A meta-analysis.
TLDR
This meta-analysis strongly suggests the use of lamivudine in the prevention of HBV vertical transmission in carrier pregnant women with the HBV DNA levels greater than 106 copies/mL and for women withthe HBV viral loads lower than 106 copy/mL. Expand
Lamivudine vs placebo or no treatment in preventing the transmission of hepatitis B virus during pregnancy: a systematic review and meta-analysis.
TLDR
Lamivudine can significantly reduce the MTCT of HBsAg and HBV DNA of neonates during the third trimester of pregnancy without severe adverse events. Expand
Comparing the Efficacy and Safety of Treating Chronic Hepatitis B Infection during Pregnancy with Lamivudine, Telbivudine, and Tenofovir: A Meta-analysis
TLDR
Treatment with LdT seemed to show more potential in resolving certain infant- and maternal-related outcomes, and nucleos(t)ide analogues might also be involved in creatine kinase elevation. Expand
Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis.
TLDR
Antenatal lamivudine administration to pregnant patients with hepatitis B is cost-effective, and frequently cost-saving, under a wide range of circumstances. Expand
Safety of lamivudine treatment for chronic hepatitis B in early pregnancy.
TLDR
LAM treatment is safe for chronic HBV-infected pregnant mothers and their fetuses with a gestational age of less than 12 wk or throughout the entire pregnancy, and the effectiveness of lamivudine treatment for blocking mother-to-infant transmission of hepatitis B virus was evaluated. Expand
Hepatitis B in pregnancy
TLDR
One in six women had active HBV requiring treatment or high HBV-DNA levels that would benefit from antiviral treatment to reduce the transmission risk. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis.
TLDR
Multiple injections of HBIG in HBV carrier mothers with a high degree of infectiousness in late pregnancy, effectively and safely prevent HBV intrauterine transmission. Expand
Interruption of HBV intrauterine transmission: a clinical study.
TLDR
The risk of HBV intrauterine infection can be effectively reduced by administration of HBIG or Lamivudine in the 3(rd) trimester of HBsAg positive pregnant women. Expand
Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection
TLDR
In highly viraemic HBsAg‐positive mothers, reduction of viraemia by lamivudine therapy in the last month of pregnancy may be an effective and safe measure to reduce the risk of child vaccination breakthrough. Expand
Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors.
TLDR
Specific allelic mutations in maternal HBV and level of maternal viremia are potential predictors of vertical breakthrough infection. Expand
Vertical transmission of hepatitis B virus despite maternal lamivudine therapy
TLDR
Lamivudine therapy might not prevent perinatal transmission of HBV infection in every newborn, and complete sequence homology and a similar precore mutation was found in the mother and child, indicating vertical transmission. Expand
Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection.
TLDR
HBIG is potent to cut down HBV intrauterine infection rate significantly when administered to pregnant women regularly during late pregnancy, and showed ascendant trend as HBV DNA levels in the peripheral blood increased before delivery. Expand
Evaluation of therapeutic effect in HBV vertical transmission by lamivudine treatment combined with active-passive immunization for pregnant women
TLDR
Lamivudine and HBIG effectively block the vertical transmission of HBV, inhibit the HBV infection in infants and increase the positive seroconversion rates of anti-HBs and antibody titre at 12-months’ infants. Expand
[The role of placenta in hepatitis B virus intrauterine transmission].
TLDR
HBV infection of placental capillary endothelial cell is a major risk factor of intrauterine transmission and the main timing is possibly in the third-trimester of pregnancy. Expand
[Effect of high viral hepatitis B virus DNA loads on vertical transmission of hepatitis B virus in late-pregnant women].
TLDR
The pregnant women's HBV DNA loads could be obviously decreased from high viral loads after they take lamivudine from 36 weeks' gestation, but it might not reduce the maternal-fetal vertical transmission of HBV infection. Expand
Long-term efficacy of immunization against hepatitis B virus in infants at high-risk analyzed by polymerase chain reaction.
TLDR
It is indicated that most of HBV infections occur early, during the first year, and that immunization against HBV effectively protects infants at high-risk against viral transmission, at least up to 4-6 years of age. Expand
...
1
2
3
4
5
...